Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275639 · ClinicalTrials.gov registry record · Phase 4
The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant
A Phase 4 study of Liver Transplant Recipients, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT00275639 is a Phase 4 study of Liver Transplant Recipients that has completed, run by Mayo Clinic. The registered enrollment target is 62 participants, below the 72-participant average among 3 other Liver Transplant Recipients trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00275639, a Phase 4 study of Liver Transplant Recipients, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to study the effects, both good and bad, of calcineurin inhibitors and the drug Cozaar (losartan), on kidney function and kidney scarring following a liver transplant.
Conditions Studied
Interventions
- DRUG Cozaar
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275639
The ClinicalTrials.gov registry entry for NCT00275639 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 3 other Liver Transplant Recipients trials with a reported enrollment target (14% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Transplant Recipients appearing as the primary indexed condition, and to 1 intervention - of which Cozaar is the first listed.
NCT00275639 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00275639 about?
NCT00275639 is a clinical study titled "The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant". This research study is being done to study the effects, both good and bad, of calcineurin inhibitors and the drug Cozaar (losartan), on kidney function and kidney scarring following a liver transplant.
What is the current status of trial NCT00275639?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2004-12. Estimated completion is 2007-08.
What conditions does trial NCT00275639 study?
This clinical trial studies the following conditions: Liver Transplant Recipients.
What interventions are being tested in trial NCT00275639?
The interventions under investigation include: Cozaar (DRUG).
Who is sponsoring clinical trial NCT00275639?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00275639 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.